A New Monoclonal Anti-A Antibody BIRMA-1

McDonald, D.F.; Thompson, J.M.

doi:10.1159/000461314

Vox Sanguinis

1991

DOI: 10.1159/000461314

|View full text |Cite

A New Monoclonal Anti-A Antibody BIRMA-1

D.F. McDonald¹,

J.M. Thompson²

Abstract: A monoclonal anti-A antibody, BIRMA-1, has been evaluated and found to be eminently suitable as a blood-grouping reagent. The culture supernatant is potent, avid and specific as demonstrated by its reactivity with a large sample of donor bloods tested manually and on the Olympus PK 7100 automated blood grouping machine. Over 100 cord blood samples were tested manually, and all were correctly grouped using this antibody. No false-positive reactions were obtained with papainized group B cells. Reagent prepared f… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1998

2017

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Shiga Toxin Binds Human Platelets via Globotriaosylceramide (P^kAntigen) and a Novel Platelet Glycosphingolipid

Cooling

Walker²,

Gille³

et al. 1998

Infect Immun

104

View full text Add to dashboard Cite

Hemolytic-uremic syndrome is a clinical syndrome characterized by acute renal failure, microangiopathic hemolytic anemia, and thrombocytopenia that often follows infection by Shiga toxin- or verotoxin-producing strains of Escherichia coli. Because thrombocytopenia and platelet activation are hallmark features of hemolytic-uremic syndrome, we examined the ability of Shiga toxin to bind platelets by flow cytometry and high-performance thin-layer chromatography (HPTLC) of isolated platelet glycosphingolipids. By HPTLC, Shiga toxin was shown to bind globotriaosylceramide (Gb3) and a minor platelet glycolipid with anRf of 0.03, band 0.03. In a survey of 20 human tissues, band 0.03 was identified only in platelets. In individuals, band 0.03 was expressed by 20% of donors and was specifically associated with increased platelet Gb3 expression. Based on glycosidase digestion and epitope mapping, band 0.03 was hypothesized to represent a novel glycosphingolipid, IV3-β-Galα1-4galactosylglobotetraosylceramide. Based on incidence, structure, and association with increased Gb3 expression, band 0.03 may represent the antithetical Luke blood group antigen. By flow cytometry, Shiga toxin bound human platelets, although the amount of Shiga toxin bound varied in donors. Differences in Shiga toxin binding to platelet membranes did not reflect differences in platelet Gb3 expression. In contrast, there was a loose association between Shiga toxin binding and decreasing forward scatter, suggesting that Shiga toxin and verotoxins bind more efficiently to smaller, older platelets. In summary, Shiga and Shiga-like toxins may bind platelets via specific glycosphingolipid receptors. Such binding may contribute to the thrombocytopenia, platelet activation, and microthrombus formation observed in hemolytic-uremic syndrome.

show abstract

Shiga Toxin Binds Human Platelets via Globotriaosylceramide (P^kAntigen) and a Novel Platelet Glycosphingolipid

Cooling

Walker²,

Gille³

et al. 1998

Infect Immun

104

View full text Add to dashboard Cite

show abstract

ABO serology in a case of persistent weak A in a recipient following a group O–matched unrelated bone marrow transplant

et al. 2017

View full text Add to dashboard Cite

HLA-matched hematopoietic stem cell transplantation (HSCT) from red blood cell (RBC)-incompatible donors is not uncommon. The engraftment process following ABO-incompatible allogeneic HSCT results in the transition from patient blood group to donor blood group in the recipient. In contrast, most non-hematopoietic tissues retain expression of the patient's original blood group for life, and these antigens may adsorb from the plasma onto the donor-derived RBCs. Correct serologic interpretation of the ABO blood group during this engraftment process can be difficult. We present the serologic findings of a 15-year-old girl of Maori descent, who was diagnosed with acute myeloid leukemia and transplanted with an HLA-matched unrelated group O, D+ bone marrow. Despite engraftment, her RBCs showed persistence of weak A. This case report showcases the importance of awareness and correct serologic interpretation of weak persistence of recipient ABH substance on the patient's RBCs for clinical decision-making, blood component support, and patient wellbeing. Immunohematology 2017;33:99-104.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A New Monoclonal Anti-A Antibody BIRMA-1

Cited by 2 publications

References 3 publications

Shiga Toxin Binds Human Platelets via Globotriaosylceramide (P^kAntigen) and a Novel Platelet Glycosphingolipid

Shiga Toxin Binds Human Platelets via Globotriaosylceramide (P^kAntigen) and a Novel Platelet Glycosphingolipid

ABO serology in a case of persistent weak A in a recipient following a group O–matched unrelated bone marrow transplant

Contact Info

Product

Resources

About

A New Monoclonal Anti-A Antibody BIRMA-1

Cited by 2 publications

References 3 publications

Shiga Toxin Binds Human Platelets via Globotriaosylceramide (PkAntigen) and a Novel Platelet Glycosphingolipid

Shiga Toxin Binds Human Platelets via Globotriaosylceramide (PkAntigen) and a Novel Platelet Glycosphingolipid

ABO serology in a case of persistent weak A in a recipient following a group O–matched unrelated bone marrow transplant

Contact Info

Product

Resources

About

Shiga Toxin Binds Human Platelets via Globotriaosylceramide (P^kAntigen) and a Novel Platelet Glycosphingolipid

Shiga Toxin Binds Human Platelets via Globotriaosylceramide (P^kAntigen) and a Novel Platelet Glycosphingolipid